Health Policy
Larry Levitt, MPP
has multimedia
has audio
JAMA. 2021;325(3):215-216. doi:10.1001/jama.2020.25717
This Viewpoint posits that the US will engage in another debate about health care reform to consider expanding coverage, improving affordability, and containing costs.
-
Conversations with Dr Bauchner:
Health Care Reform in the Biden Era
-
Editorial
Health Care Is a Right, Not a Privilege: A New Series on US Health Care and Health Policy
Howard Bauchner, MD; Phil B. Fontanarosa, MD, MBA; Karen Joynt Maddox, MD, MPH
-
Conversations with Dr Bauchner:
Health Care Reform in the Biden Era
Health Policy
Timothy M. Westmoreland, JD; M. Gregg Bloche, MD, JD; Lawrence O. Gostin, JD
has multimedia
has audio
JAMA. 2021;325(3):217-218. doi:10.1001/jama.2020.25888
This Viewpoint proposes measures the incoming Biden administration can take to increase access to health insurance coverage under the Affordable Care Act (ACA) and Medicaid, including limiting short-term ACA coverage provisions, rolling back state Medicaid waivers, and simplifying Medicaid eligibility.
-
Conversations with Dr Bauchner:
Health Care Reform in the Biden Era
-
Editorial
Health Care Is a Right, Not a Privilege: A New Series on US Health Care and Health Policy
Howard Bauchner, MD; Phil B. Fontanarosa, MD, MBA; Karen Joynt Maddox, MD, MPH
-
Conversations with Dr Bauchner:
Health Care Reform in the Biden Era
Annette Rid, MD; Marc Lipsitch, DPhil; Franklin G. Miller, PhD
free access
has active quiz
has multimedia
has audio
JAMA. 2021;325(3):219-220. doi:10.1001/jama.2020.25053
This Viewpoint proposes that prioritizing all placebo-group participants in coronavirus vaccine trials as vaccine first receivers could perpetuate health inequities and compromise the chance to learn from their participation, proposing instead to limit prioritization to placebo participants who would be prioritized for vaccination anyway under NASEM or ACIP frameworks.
-
Conversations with Dr Bauchner:
Coronavirus Vaccine FDA Update
-
Conversations with Dr Bauchner:
COVID-19 Vaccines and Herd Immunity
Steven Joffe, MD, MPH
free access
has active quiz
has multimedia
has audio
JAMA. 2021;325(3):221-222. doi:10.1001/jama.2020.25127
This Viewpoint discusses the ethics of including a placebo arm in randomized trials of coronavirus vaccines once authorized vaccines have become widely available, and proposes use of adaptive platform trial designs as an optimal approach to nimbly and ethically compare future investigational COVID-19 vaccines with proven effective ones.
-
Conversations with Dr Bauchner:
Coronavirus Vaccine FDA Update
-
Conversations with Dr Bauchner:
COVID-19 Vaccines and Herd Immunity
-
Conversations with Dr Bauchner:
Coronavirus Vaccine Update With Arnold S. Monto, MD
Raina M. Merchant, MD, MSHP; Eugenia C. South, MD, MSHP; Nicole Lurie, MD, MSPH
has active quiz
has audio
JAMA. 2021;325(3):223-224. doi:10.1001/jama.2020.24514
This Viewpoint discusses the rapid spread of scientific misinformation on social media platforms throughout the COVID-19 pandemic and proposes strategies to counteract its adverse effects including surveillance of digital data and partnering with trusted messengers to engage the public and advance scientifically sound public health measures.
-
Conversations with Dr Bauchner:
Public Health Messaging in an Era of Social Media